Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck 2024 Restructuring Program (Supply Network & Commercial Optimization) — Ending Accrual Reserve Balance ($M) ($M)
Form 10-Q / 10-K Restructuring Footnote
Latest, Q2 2026
408
Period ended Jun 30, 2026
Change on a year earlier
-25.5%
548 in Q2 2025
History
8 quarters
Since Q4 2022
Sources
6
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | 2024 Restructuring Program (Supply Network & Commercial Optimization) — Ending Accrual Reserve Balance ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 408 | -25.5% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 448 | – | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 506 | -10.3% | Form 10-Q (filed 2026-08-07) ↗ |
| Q3 2025 | Sep 30, 2025 | 499 | – | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 548 | – | Form 10-Q (filed 2025-08-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 564 | -20.8% | Form 10-K (filed 2026-02-24) ↗ |
| Q4 2023 | Dec 31, 2023 | 712 | – | Form 10-K (filed 2026-02-24) ↗ |
| Q4 2022 | Dec 31, 2022 | 0 | – | Form 10-K (filed 2024-02-26) ↗ |
Cite this data
StockData. (2026). Merck 2024 Restructuring Program (Supply Network & Commercial Optimization) — Ending Accrual Reserve Balance ($M) ($M), quarterly Q4 2022–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/restr_program2024_res_tot
See every metric in the Merck KPI table. Data updated Oct 26, 2026.